DuPont Applied BioSciences Selects MBI to Collaborate on Process
Development and Scale-Up for New Bio-based Product
LANSING, Mich. (Business Wire EON/PRWEB ) December 2, 2008 --
DuPont Applied BioSciences has turned to MBI International to join the
DuPont team in evaluating the commercial viability of an important
bio-based product line. MBI
International is a leader in bridging the gap between research and
commercialization through collaborative de-risking of bio-based
technologies. MBI’s unique “Collaborative De-Risking” process
systematically addresses technological uncertainties, which impede new
technologies from getting to market.
"We are very excited that DuPont Applied BioSciences has chosen MBI as a
partner to help de-risk this important new product line," stated Dr.
Bobby Bringi, recently appointed President of MBI International. "We had
the opportunity to work with DuPont Applied BioSciences on an initial
phase of this project, and are proud that they have chosen to extend
this partnership with MBI.”
MBI International fits a unique niche in the marketplace. Virtually all
bio-based technology developments that come from the lab need to go
through a process development and scale-up stage to determine commercial
viability. Once the uncertainties or risks associated with early
technological developments are mitigated via de-risking, a company like
DuPont Applied BioSciences is better positioned to make product-related
investments.
MBI has built a multi-disciplinary team of scientists and engineers, as
well as the required pilot-plant facilities, to work collaboratively
with industry partners to help address the risks associated with
bringing bio-based technologies to market. MBI also provides
connectivity with both Michigan State University and the greater
university research community to help solve complex problems.
“DuPont Applied BioSciences is pleased to continue our collaboration
with MBI on this important new product line,” stated Scott Cunningham,
Business Development Manager – DuPont Applied BioSciences. “MBI’s well
rounded expertise, operational flexibility and excellent facilities
allowed us to successfully complete Phase I of the project. We are
confident that MBI will help us to evaluate the critical path of this
technology and identify opportunities and threats to scale-up and
commercialization.”
"DuPont is a world leading market-driven, science-based products
company, so we are pleased they have chosen to continue working with our
team," states Bringi. "De-risking high-technology developments is like
building a bridge to the market. It requires experienced partners to
work in collaboration with one another at each stage in the process from
the lab through scale-up and then to the market. From our point of view,
this relationship helps validate the strategic position we have chosen
for MBI."
About MBI
MBI partners with universities and companies involved in sustainable
technologies to bridge the gap between research and commercial
applications. With over 25 years experience in fermentation technologies
and process scale-up, MBI bundles a full spectrum of science,
engineering, operational, and business expertise with an integrated
infrastructure from laboratory bench to pilot-plant. MBI’s focus is
Industrial or White Biotechnology, which refers to the production of
fuels, chemicals, polymers, proteins and other materials from renewable
resources. Please visit www.mbi.org
for more information.
See the original story at: http://eon.businesswire.com/releases/dupont_applied/applied_biosciences/prweb1694764.htm
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/U3VtbS1Db3VwLVN1bW0tRmFsdS1Mb3ZlLVNpbmctWmVybw==
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
